ATRA

Atara Biotherapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-16

Figures on this page computed 2026-11-08 12:40 UTC

Last close

7.96USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-03-16

3.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
27.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
-42.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.27 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Against its rival

lens 4 of 9

Measure by measure

behind on 0 of 1

Profit on each unit of sales27.1%-2.0%Ahead
Higher is better here.
Return on the capital it usesn/an/an/a
Higher is better here.
Sales growth over five yearsn/a7.7%n/a
Higher is better here.
Debt against equityn/a1.17n/a
Lower is better here.
Gross marginn/a48%n/a
Higher is better here.
Price against earnings3.0xn/an/a
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against Champions Oncology, Inc., ATRA is behind on 0 of 1 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Profit on each unit of sales27.1%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself
Return on the capital it usesn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself
Sales growth over five yearsn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself
Gross marginn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself
Price against earnings3.0x
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
The filing itself